Selected article for: "CAL development and IVIG resistance CAL development"
Author: Kang, Soo Jung; Kim, Nam Su
Title: Association of Toll-like receptor 2-positive monocytes with coronary artery lesions and treatment nonresponse in Kawasaki disease
  • Document date: 2017_7_31
    • ID: tk1bxztw_43
    Snippet: This study showed that FTLR2% before the initial treatment of patients with KD was significantly high in the CAL (+) group than that in the CAL () group, and this was a more sensitive, predictive parameter for CALs than sIL10. Furthermore, FTLR2% tended to be higher in IVIG nonresponders compared to that in the IVIG res ponders, and this frequency could predict IVIG resistance with a sensitivity comparable to that of sIL10. To the best of our kno.....
    Document: This study showed that FTLR2% before the initial treatment of patients with KD was significantly high in the CAL (+) group than that in the CAL () group, and this was a more sensitive, predictive parameter for CALs than sIL10. Furthermore, FTLR2% tended to be higher in IVIG nonresponders compared to that in the IVIG res ponders, and this frequency could predict IVIG resistance with a sensitivity comparable to that of sIL10. To the best of our knowle dge, our study is the first clinical study to utilize FTLR2% to predict CAL development and IVIG resistance in patients with KD and to compare its feasibility with that of sIL10.

    Search related documents:
    Co phrase search for related documents
    • CAL development and ivig resistance CAL development: 1, 2, 3, 4, 5, 6, 7, 8
    • CAL group and IVIG resistance: 1, 2, 3, 4
    • CAL group and ivig resistance CAL development: 1, 2, 3
    • CAL group group and IVIG resistance: 1, 2
    • CAL group group and ivig resistance CAL development: 1, 2
    • clinical study and IVIG resistance: 1, 2
    • initial treatment and IVIG resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • initial treatment and ivig resistance CAL development: 1, 2, 3
    • initial treatment and sIL10 comparable sensitivity: 1
    • initial treatment and sIL10 comparable sensitivity IVIG resistance: 1
    • initial treatment and sIL10 comparable sensitivity IVIG resistance predict: 1
    • IVIG resistance and KD patient: 1
    • IVIG resistance and sIL10 comparable sensitivity: 1
    • IVIG resistance and sIL10 comparable sensitivity IVIG resistance: 1
    • IVIG resistance and sIL10 comparable sensitivity IVIG resistance predict: 1